SCM
AEGR

Sarissa Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Sarissa Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,649,000
Closed -$7.87M – 15
2016
Q3 		$7.87M Hold
2,649,000
– – 1.81% 8
2016
Q2 		$3.95M Buy
2,649,000
+69,000
+3% +$158K 1.12% 12
2016
Q1 		$9.55M Hold
2,580,000
– – 2.1% 10
2015
Q4 		$26.1M Buy
2,580,000
+25,000
+1% +$301K 5.07% 8
2015
Q3 		$34.7M Buy
2,555,000
+518,171
+25% +$9.23M 8.58% 5
2015
Q2 		$38.6M Buy
2,036,829
+399,374
+24% +$8.64M 8.89% 5
2015
Q1 		$42.9M Buy
+1,637,455
New +$41.7M 9.04% 5

Sarissa Capital Management's AEGR Position: Q4 2016 in Review

Sarissa Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 2,649,000 shares — an estimated $7.87M sold.

Sarissa Capital Management first reported a position in AEGR in Q1 2015 and held it in 7 quarters. The position peaked at $42.9M in Q1 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Sarissa Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Sarissa Capital Management sold 2,649,000 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $7.87M.
  • Sarissa Capital Management first reported a position in Aegerion Pharmaceuticals in Q1 2015 and held it in 7 quarters.
  • Sarissa Capital Management's Aegerion Pharmaceuticals position peaked at $42.9M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Sarissa Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.